IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Human Journals
Review Article
March 2021 Vol.:20, Issue:4

Review Article on Mental Confusion

IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Bharat Vidhate*, Preeti Gupta, Vikas Gupta, Kailash Gupta, Vijay Gupta, Laxmi Gupta

Professor. Department of pharmacology, Ideal College of Pharmacy & Research, Kalyan, India

Bachelor of Pharmacy, Ideal College of Pharmacy & Research, Kalyan, India

Submitted: 09 February 2021
Revised: 28 February 2021
Accepted: 20 March 2021

HUMAN JOURNALS
www.ijppr.humanjournals.com

Keywords: Mental confusion, Delirium, Brain disorder, Schizoid personality disorder (SPD), Dementia

ABSTRACT

Wooziness is an unsettling influence of cognizance, insight, and discernment that happens habitually in medicinally sick patients. Even though it is related to expanded horribleness and mortality, it is frequently not perceived and treated by doctors. Inclining factors are accepted to have multiplicative impacts and incorporate dementia, progressed age, and male sex, as of late created models take into account the assessment of the danger of creating incoherence during hospitalization, in light of inclining components and intense extra stressors. Even though it has been demonstrated to be effective, the counteraction of incoherence is underutilized. Avoidance comprises of forceful administration of realized danger factors and early location. Restricted information exists to help explicit pharmacological mediations for its treatment. In this article, the benefit capable distributed writing concerning the avoidance and treatment of incoherence is efficiently inspected.

INTRODUCTION:

The phenomenon of suicidal behavior comprises a diverse set of actions, including suicidal thoughts, suicide attempts, and actual death by suicide. Given the significant differences between these behavioral categories, suicidologists are aware that the generalizability of research findings is dramatically affected by the population selected for the study. In several studies, MSSAs have been found to closely resemble suicide completers and to be twice as liable as other suicide attempters to subsequently complete suicide. Thus, this group can help us understand the dynamics, processes, and risk factors that may predict suicide. Schizoid personality disorder (SPD) can be viewed as the extreme of interpersonal difficulty. According to DSM-5, SPD is associated with social detachment, significant behavioral impairment, and emotional aloofness. Thus, SPD symptoms can be represented mostly by social withdrawal, low interest in activities, lack of motivation as well as significant affective indifference(1).

Consequently, accurate prevalence estimates for SPD are scarce, but they tend to range between 1% and 5% of the general population. Some theoreticians have emphasized the presence of “secret” schizoid tendencies, in which the characteristics of the schizoid personality remain in the individual's subjective internal world, stressed that only by asking the individuals of their subjective experience, the presence of schizoid difficulties of emotional intimacy can be detected. Thus, it may be possible that SPD's actual prevalence is much higher than official estimates. SPD symptoms are related to higher levels of mental pain and recurrent depression while on the outside, the individual displays an engaging, interactive interpersonal pattern. However, to the best of our knowledge, no studies have directly explored suicide behavior among SPD individuals. (2). Some research findings have revealed an association between schizoid personality disorder and homicide and violence, revealed that general schizoid tendencies, beyond those characterizing the mental pain dimension, contributed to more lethal suicide attempts. However, the question of identifying the prominent symptoms facilitating high lethal suicide attempts having higher levels of intent remains open. Resolving this question will enable us to target assessment and intervention strategies to the specific factors contributing to the more perilous suicide attempts. The present study was designed to determine the roles of various mentalizing abilities and cognitive biases in leading to religious and paranormal beliefs and to believe in supernatural purposes. Even though faith in the existence of a supernatural realm unites religious and other paranormal beliefs, religious and non-religious paranormal beliefs have

seldom been simultaneously addressed in the research literature. Seeing the purpose behind random life-events, in turn, has traditionally not been included in these studies at all. Recently, however, several scholars have brought up that these beliefs by simultaneously studying different types of beliefs, abilities, biases, and the paths in between, we hope to increase our understanding of what it is that draws people to believe in the supernatural(1). Delirium is caused by an acute organic process, which is a physically identifiable structural, functional, or chemical problem in the brain that may arise from a disease process *outside* the brain that nonetheless affects the brain. It may result from an underlying disease process (e.g. infection, hypoxia), side effects of a medication, withdrawal from drugs, over-consumption of alcohol, usage of hallucinogenic deliriants, or from any number of factors affecting one's overall health (e.g. malnutrition, pain, etc.).

Delirium may be difficult to diagnose without the proper establishment of a person's usual mental function. Without careful assessment and history, delirium can easily be confused with some psychiatric disorders or chronic organic brain syndromes because of many overlapping signs and symptoms in common with dementia, depression, psychosis, etc. Delirium may manifest from a baseline of existing mental illness, baseline intellectual disability, or dementia, without being due to any of these problems(3).

DEFINITION:

Confusion occurs when a person has difficulty understanding a situation or has disordered or unclear thoughts. It can be accompanied by memory loss, disorientation, or the inability to think quickly. Confusion can increase slowly over time or come on abruptly, depending upon the cause. It may be associated with serious infections, some chronic medical conditions, head injury, brain or spinal cord tumor, delirium, stroke, or dementia. It can also be caused by alcohol or drug intoxication, sleep disorders, chemical or electrolyte imbalances, vitamin deficiencies, or medications. It can also occur in the period following a seizure or as a result of hypothermia(4).

SIGN AND SYMPTOMS:

Confusion is a change in mental status in which a person is not able to think with his or her usual level of clarity. Frequently, confusion leads to the loss of the ability to recognize people and or places or tell time and the date. Feelings of disorientation are common in confusion, and decision-making ability is impaired(4) (5).

Related Symptoms & Signs:

- Memory Loss
- Altered Mental Status
- Paranoia

Other causes of confusion:

- Carbon Monoxide Exposure
- Delirium
- Dissociative Disorders
- Electrolyte Imbalances
- Hospitalization (Particularly in the Elderly)
- Korsakoff Syndrome
- Liver Failure
- Medications
- Nutritional Deficiencies
- Sleep Deprivation
- Toxins(6).

CAUSES OF MENTAL CONFUSION:

Mental confusion may have more than one cause. This is especially true if a person is weak or very sick. Finding the cause is important so their doctor can choose the best treatment. Here are some possible causes.

Medications that can cause mental confusion include:

- Chemotherapy drugs
- Pain medications

- Anti-nausea or allergy medications
- Steroid medications
- Sleep medications
- New medications for other conditions

A person may develop confusion or delirium if they suddenly stop taking certain medications, especially if they have previously been taking these medications for a prolonged period(4).

Organ problems: Mental confusion or delirium can happen if certain organs are not working correctly. These can include the liver, kidneys, heart, or lungs. Seizures or cancer that has spread to the brain can cause delirium.

Problems with fluid and electrolyte balance: The balance of fluids and minerals called electrolytes keeps your brain and body working correctly. Having much more or much less than normal can cause mental confusion. Things that can upset the balance include:

- Too much of the mineral calcium in the blood.
- Dehydration. This might happen if you are nauseated, vomiting, or having trouble swallowing. Diarrhea and urinating a lot can also cause dehydration.
- Too much fluid in the body. Heart, kidney, or liver failure can cause this.
- Too much or too little sugar in the blood(7)

Infection- Bladder, lung (pneumonia), brain, and blood infections (sepsis) can cause mental confusion and delirium. Sepsis is a life-threatening condition that happens when an infection spreads to your bloodstream.

Not enough oxygen in the blood. Health problems that cause low levels of oxygen in the blood can cause mental confusion. These include lung or heart problems, blood clots, and sleep problems(8).

Confusion may be caused by different health problems, such as:

Alcohol or drug intoxication

Brain tumor

Head trauma or head injury (concussion)

Fever

Fluid and electrolyte imbalance

Illness in an older person, such as loss of brain function (dementia)

Illness in a person with existing neurological disease, such as a stroke

Infections

Lack of sleep (sleep deprivation)

Low blood sugar

Low levels of oxygen (for example, from chronic lung disorders)

Medicines

Nutritional deficiencies, especially niacin, thiamine, or vitamin B12

Seizures

A sudden drop in body temperature (hypothermia)(5)

MECHANISM:

Acetylcholine is the main excitatory neurotransmitter in the CNS and skeletal muscle. There are 2 types of acetylcholine receptors: nicotinic receptor (in the neuromuscular junction and autonomic ganglia) and muscarinic receptor. Classic anticholinergic drugs causing delirium act on muscarinic receptors and do not affect skeletal muscle, which expresses nicotinic receptors. These agents can be termed antimuscarinics. Muscarinic receptors have 5 subtypes. Different subtypes are expressed throughout the body to receive acetylcholine that is released preganglionically in sympathetic and parasympathetic synapses. In the brain, acetylcholine controls higher cognitive processes, such as learning and memory(9). CNS acetylcholine levels have an impact on multiple neurodegenerative diseases. For example, cholinergic deficit and loss of cholinergic neurons in the basal forebrain are central to cognitive impairment in Alzheimer's disease.M4 and M5 receptors are involved in Parkinson’s disease and schizophrenia. Antimuscarinic compounds that bind to the M1 receptor subtype produce the most cognitive dysfunction and those more selective against M3 (as in the case of certain

overactive bladder medications) may produce the least. The penetrability of the blood-brain barrier, administration of multiple drugs, and rate of CNS metabolism also contribute to the severity of CNS toxicity. Toxicity is amplified in the setting of blood-brain barrier breakdowns, such as in the case of older age, infection, multiple sclerosis, and diabetes. Patients with baseline cognitive dysfunction and dementia are also at the highest risk of developing delirium(10).

PATHOPHYSIOLOGY:

Delirium is a syndrome of acutely altered mental status that has the core elements of inattention and fluctuating course and multiple associated features including altered arousal, disorganized thinking, perceptual disturbances, psychosis, and sleep-wake cycle disturbance(11).The increasingly apparent morbidity and mortality associated with delirium in the ICU promotes the search for possible pharmacologic prevention strategies. While such prophylactic measures are still experimental, some promising studies have shown a possible role for premedication certain at-risk patient populations in the interest of reducing delirium incidence and resultant sequelae. Most of these studies have been done in non-ICU populations, are relatively underpowered, and remain mixed at best. Those studies limited to the ICU population are far fewer(12). Delirium has a multifactorial origin, including neurotransmitter changes, endothelial dysfunction and inflammation. The phenotype or expression of delirium has traditionally been categorized as hypoactive, hyperactive or mixed delirium. However, other phenotypes have gained interest in recent years, due to differences in prognosis and precipitating factors, such as those associated with sedative drugs, of terminal illness, associated with a metabolic cause/hypoxia/sepsis, subsyndromal delirium, persistent or chronic delirium, or delirium superimposed on a previous dementia. A reversible cause of delirium in hospitalized patients is the administration of drugs such as benzodiazepines, anticholinergics, or opiates. The prognosis in these cases is favorable when the drug is withdrawn, without long-term complications(11). Delirium is a heterogeneous syndrome and has multiple phenotypes. Delirium is frequently phenotype by psychomotor activity: hypoactive, hyperactive, and mixed. Hyperactive delirium is characterized by motor agitation, restlessness, and sometimes aggressiveness. Hypoactive delirium is characterized by motor retardation, apathy, slowing of speech, and patients can appear to be sedated. Mixed delirium is a combination of hyperactive and hypoactive delirium. Hypoactive delirium is the most common subtype and easier to miss because of its subtle clinical presentation. The spectrum of hyperactive delirium includes excited delirium syndrome (ExDS), which has

traditionally been used in the forensic literature to describe findings in a subgroup of patients with delirium who suffered lethal consequences from their untreated severe agitated behaviors'. Hypoactive carries the worst prognosis and has been associated with poorer in-hospital and long-term mortality(13). Functional neurological disorders represent about 6% of consultations in neurology outpatient clinics, and functional motor and sensory symptoms represent 18% of diagnoses in patients with "symptoms unexplained by organic disease(14). In addition to the brain hitting against the cranium, any rotational movement to the brain following the impact may stretch, and sometimes tear, axons within white matter tracts of the brain, which is known as "diffuse axonal injury." Although traditional CT scans are unable to detect these injuries, modern imaging techniques such as altered fractional anisotropy using diffusion tensor imaging and MRI show promise to detect these changes. Using rodent models, there is recent evidence to suggest this type of injury may impair neuronal function, although the causes of this dysfunction are currently unclear. Some research suggests diffuse axonal injury may induce neuronal degeneration as evidenced by increased Fluoro-Jade staining, whereas other research suggests it may only induce neuronal atrophy due to axotomy of the axon initial segment. For the latter, 2 types of axonal abnormality have been observed. The first is progressive swellings along the axon termed "bulbs" that eventually lead to axonal disconnection and loss of function. The second is a production of axonal varicosities and is thought to be due to microtubule breakage, thus slowing axonal transport to cause the varicosities. It has been proposed these abnormalities may lead to delayed secondary disconnection and/or prolonged neuronal dysfunction(15).

DIAGNOSIS:

A systematic evaluation of the patient's complaints is the cornerstone of a successful diagnosis. The evaluation is incomplete without the history of a bed partner or a family member who has witnessed such an event. Many of these events may go unnoticed if the patient is sleeping alone. An accurate description of the event is particularly helpful, including information about awareness after the event and recall of events in the morning. Video recordings of the event at home may provide vital clues to the diagnosis(16).

Other diagnostic criteria are suggested in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5).70 both of these diagnostic schemas are largely in agreement for features that are essential for diagnosis. However, there are subtle differences, as follows:

1. ICSD-3 labels abnormal NREM sleep arousals under a common condition called “disorder of arousals,” which is further subclassified, whereas DSM-5 does not define any such condition.

2. ICSD-3 labels arousals devoid of terror and ambulation outside of bed as confusional arousals; however, no similar condition is defined by DSM-5. Moreover, sleep-related sexual behaviors (sexsomnia) are classified as a subtype of confusional arousal in ICSD-3, whereas in DSM-5 sex somnias are classified as a variant of sleepwalking.

3. DSM-5 identifies SRED as a subtype of sleepwalking, whereas ICSD-3 classifies it as a distinct parasomnia from the disorder of arousals. A formal evaluation should also include a history of comorbid sleep disorders (such as OSA, RLS with PLMD), previous psychiatric history, or use of any psychotropic medications. Assessment of any functional daytime impairment or excessive daytime sleepiness is also important(17).

The core cognitive deficit in delirium is an acute disturbance in attention as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). Attention is a broad cognitive construct including the ability to direct, focus, sustain, and shift cognitive ability. Importantly, the DSM-5 recognizes that patients who are acutely unable to attend due to deficiencies in arousal should be considered as having delirium, because arousal is required for assessment of any cognitive domain(18). The lack of standardization in the assessment of DSD may have potential significant clinical and research implications. The DSM-5 and the ICD-10 do not provide clinicians with indications of specific tests for assessment of attention or additional cognitive disturbances in cognition or altered level of arousal. Importantly, the assessment or inclusion of preexisting cognitive impairment is also not addressed by either the DSM-5 or ICD-10. Meagher et al12 have recently attempted to provide a standardized approach to the use of the DSM-5 criteria for delirium to avoid “confusion” even with the use of the standard reference. As the DSM-5 and the ICD-10 are considered the standard reference for the diagnosis of delirium, then several practical limitations should be considered. First, attention has multiple domains,13 and there is not a clear DSM-5 and ICD-10 guidance regarding which domain or attention test should be used in patients with dementia, dementia stage, or dementia subtypes. Second, the clinician is currently not provided with clear and predetermined methodology for how to ascertain the time of onset of delirium, the change from baseline, and fluctuation over the day(19).

TREATMENT:

Responses were classified according to the providers in the sector of mental health services — psychiatrist, another mental health specialist, general medical provider (e.g., a general medical doctor or a nurse practitioner), or complementary–alternative medical provider.

Drug treatment for mental confusion has been extensively studied. Since there is no robust mortality or long-term benefits, the goal of pharmacological therapy should be to control agitation and calm the patient, while avoiding Sedation. In specific circumstances, such as agitation, they may have a role in the treatment, but this is usually in the minority. Whenever possible, the oral route is preferred over injections to minimize discomfort of the injection, subsequent agitation, and arrhythmia(20).

Treatment at this stage is largely pharmacological and includes propofol 0.51 mg kg 1, fentanyl 12 mcg kg1, or midazolam 0.1 mg kg1 i.v.13 although these measures have been studied as preventive strategies at the end of surgery; it is surprising that they have not been evaluated as treatments. All of these measures can delay discharge from PACU(21). Drugs should be avoided as far as possible in patients who are confused or in delirium, all medication should be reviewed and unnecessary drugs discontinued. When medication is essential the lowest possible dose should be used and barbiturates and long-acting benzodiazepines (e.g. diazepam, clonazepam) avoided. When the patient's behavior interferes with medical care or causes distress, sedation must be given; haloperidol is most commonly used but should be tapered as quickly as possible. Atypical antipsychotics (risperidone, olanzapine, ketiapine) can be helpful in low dosages and sometimes valproate, donepezil and ondansetron may be effective. There is no evidence that prophylaxis with haloperidol is effective, although in patients in whom delirium tremens is predicted, chlordiazepoxide may be prophylactic(22). Nonpharmacologic treatment approaches focused on consultation by geriatrician or psychiatrist and follow-up by a liaison nurse, orientation, therapeutic activities/cognitive stimulation, provision of familiar items and family presence, optimizing sensory input, avoidance of restraints, early mobilization, nutritional supplements, and comprehensive discharge planning. Two of the RCTs reported higher rates of recovery from delirium in the intervention group, but did not decrease mortality and had no significant effect on length of hospital stay. Other non RCTs showed that nonpharmacologic treatment had benefited in at least one of the following outcomes: delirium duration, cognitive or

physical function, length of stay, or costs. A recent clinical practice guideline on the management of delirium recommends a multicomponent intervention(23).

PREVENTION:

A variety of other drugs have been used for the prevention and treatment of ED, and many have been reported. Measures advocated include sedative/ anxiolytic pre-emptive treatments that include benzodiazepines and a-2 agonists. While oral midazolam as a premedication does not appear to prevent ED, an i.v. dose of 0.03 mg kg1 at the end of squint surgery has been reported to be effective. In 2013, Zhang and colleagues performed a meta-analysis on a total of 447 children, which saw that the prophylactic oral administration of midazolam before operation 10e45 min before induction significantly decreases the incidence of ED in pediatric patients.

A drug that has received significant attention recently in smoothing emergence from anesthesia in children is dexmedetomidine(24). This a-2 agonist has limited availability in the UK at present, but a recent meta-analysis by Pickard and colleagues and a systematic review suggests that both dexmedetomidine and clonidine can have a significant impact on reducing the incidence of ED, but at the expense of prolonged recovery times. An intraoperative infusion of dexmedetomidine at 0.2e1 mcg kg1 h1 can significantly reduce the incidence of ED. However, more simply, a dose of 0.3 mcg kg1 at the end of surgery has been reported to reduce the incidence of ED from 47% to 5%. In comparative studies, dexmedetomidine is superior to a propofol bolus of 1 mg kg1 at the end of surgery. Dexmedetomidine has many features, making it an ideal agent to prevent or treat ED: with analgesic, sedative, and anti-emetic properties.

Ketamine, when administered intranasally in a dose of 2 mg kg1 as a premedication, was found to reduce the incidence of emergence agitation. A single bolus dose of 0.25 mg kg1 given intravenously 10 min before the end of surgery also appears to be effective but may prolong recovery time and also cause an increase in postoperative nausea and vomiting. Reduction in the incidence of ED was seen after a bolus dose of magnesium sulphate (30 mg kg1) followed by 10 mg kg1 h1 infusions for adenotonsillectomy, but this has been attributed to improved analgesia. Dexamethasone 0.2 mg kg1 before an operation has also been found effective in reducing ED(25).

Prevention of delirium can be targeted towards reducing the risk and incidence of delirium (primary prevention) or towards early detection and treatment (secondary prevention). A Cochrane review has summarized the RCT evidence for delirium prevention. The review incorporates six diverse, surgical studies, four of which are underpowered and inconclusive (b90 subjects), and two of which are highlighted below. Evidence that has greater clinical relevance has accrued from nonrandomized studies. In summary, the evidence suggests that health care systems should routinely incorporate protocols to detect and ameliorate risk factors for delirium. Many risk factors for delirium have been identified, many of which are susceptible to modification (e.g., hearing and visual impairment, medication, electrolyte disturbances, infections, environmental factors, urinary catheterization, nutrition, pain, and constipation), and inappropriate medications may be the sole precipitant for delirium in 12–39% of cases(26).

CONCLUSION:

Delirium is a typical reason for mortality and dreariness in more established individuals in medical clinic, and demonstrates extreme ailment in more youthful patients. Distinguishing proof of danger factors, schooling of proficient carers, and a deliberate way to deal with the executives can improve the result of the condition. Doctors ought to know that wooziness victims frequently have a consciousness of their experience, which might be given a false representation of by their fluctuating handle of the real world.

REFERENCES:

1. Levi-Belz Y, Gvion Y, Levi U, Apter A. Beyond the mental pain: A case-control study on the contribution of schizoid personality disorder symptoms to medically serious suicide attempts. Compr Psychiatry. 2019 Apr;90:102–9.
2. Burns A. Delirium. J Neurol Neurosurg Psychiatry. 2004 Mar 1;75(3):362–7.
3. Delirium. In: Wikipedia [Internet]. 2021 [cited 2021 Jan 7]. Available from: https://en.wikipedia.org/w/index.php?title=Delirium&oldid=998337037
4. Khan A, Halligan K, Greenberg B. WHAT'S THE CONFUSION? Chest. 2019 Oct;156(4):A2166.
5. Confusion [Internet]. Healthgrades. 2014 [cited 2021 Jan 7]. Available from: https://www.healthgrades.com/right-care/symptoms-and-conditions/confusion
6. Tani M, Kanai C, Ota H, Yamada T, Watanabe H, Yokoi H, et al. Mental and behavioral symptoms of person's with Asperger's syndrome: Relationships with social isolation and handicaps. Res Autism Spectr Disord. 2012 Apr;6(2):907–12.
7. What's Causing Your Memory Loss? - HelpGuide.org [Internet]. https://www.helpguide.org. [cited 2021 Jan 7]. Available from: https://www.helpguide.org/harvard/whats-causing-your-memory-loss.htm
8. Grigolon RB, Gerchman F, Schöffel AC, Hawken ER, Gill H, Vazquez GH, et al. Mental, emotional, and behavioral effects of ketogenic diet for non-epileptic neuropsychiatric conditions. Prog Neuropsychopharmacol Biol Psychiatry. 2020 Aug;102:109947.

9. Sequeira RP. Central nervous system stimulants, drugs that suppress appetite, and drugs used in Alzheimer's disease. In: Aronson JK, editor. Side Effects of Drugs Annual [Internet]. Elsevier; 2001 [cited 2021 Jan 28]. p. 1–11. Available from: http://www.sciencedirect.com/science/article/pii/S0378608001800064
10. Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther. 2008 Feb 1;117(2):232–43.
11. Cortés-Beringola A, Vicent L, Martín-Asenjo R, Puerto E, Domínguez-Pérez L, Maruri R, et al. Diagnosis, prevention, and management of delirium in the intensive cardiac care unit. Am Heart J. 2021 Feb;232:164–76.
12. Bledowski J, Trutia A. A Review of Pharmacologic Management and Prevention Strategies for Delirium in the Intensive Care Unit. Psychosomatics. 2012 May;53(3):203–11.
13. Lee S, Gottlieb M, Mulhausen P, Wilbur J, Reisinger HS, Han JH, et al. Recognition, prevention, and treatment of delirium in emergency department: An evidence-based narrative review. Am J Emerg Med. 2020 Feb;38(2):349–57.
14. Baizabal-Carvallo JF, Hallett M, Jankovic J. Pathogenesis and pathophysiology of functional (psychogenic) movement disorders. Neurobiol Dis. 2019 Jul;127:32–44.
15. Dixon KJ. Pathophysiology of Traumatic Brain Injury. Phys Med Rehabil Clin N Am. 2017 May;28(2):215–25.
16. Modi RR, Camacho M, Valerio J. Confusional Arousals, Sleep Terrors, and Sleepwalking. Sleep Med Clin. 2014 Dec;9(4):537–51.
17. Delirium. Am Fam Physician. 2003 Mar 1;67(5):1027–34.
18. Delirium - Neurologic Disorders [Internet]. MSD Manual Professional Edition. [cited 2021 Jan 7]. Available from: https://www.msdmanuals.com/professional/neurologic-disorders/delirium-and-dementia/delirium
19. Morandi A, Davis D, Bellelli G, Arora RC, Caplan GA, Kamholz B, et al. The Diagnosis of Delirium Superimposed on Dementia: An Emerging Challenge. J Am Med Dir Assoc. 2017 Jan;18(1):12–8.
20. Maldonado JR. Acute Brain Failure. Crit Care Clin. 2017 Jul;33(3):461–519.
21. McCurdy AP, Lamboglia CG, Lindeman C, Mangan A, Wohlers B, Sivak A, et al. The physical activity sector within the treatment of mental illness: A scoping review of the perceptions of healthcare professionals. Ment Health Phys Act. 2020 Oct;19:100349.
22. Bates D. Confusion and delirium. Medicine (Baltimore). 2009 Feb;37(2):81–3.
23. Flaherty JH, Yue J, Rudolph JL. Dissecting Delirium. Clin Geriatr Med. 2017 Aug;33(3):393–413.
24. MacLullich AM, Ferguson KJ, Miller T, de Rooij SE, Cunningham C. Unravelling the pathophysiology of delirium: a focus on the role of aberrant stress responses. J Psychosom Res. 2008 Sep;65(3):229–38.
25. flaherty1998.pdf.
26. Young J, Leentjens AF, George J, Olofsson B, Gustafson Y. Systematic approaches to the prevention and management of patiens with delirium. J Psychosom Res. 2008 Sep;65(3):267–72.